Clinical trial
An Observational Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium
NCT03096990 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium
- Lead sponsor
- Amgen
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 21, 2017
- Completion date
- December 27, 2018
- Enrollment
- 106 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.